Clinical Trials
4 trialsNCT04799275 2026-05-13
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT05413018 2026-04-28
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT02494258 2026-04-02
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
Phase 2 Completed
NCT05141682 2026-03-03
Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1/2 Active not recruiting